drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy)
drug_description
Off-the-shelf allogeneic CAR T-cell therapy engineered to express a CAR targeting CLL-1 (CLEC12A) to activate T-cell cytotoxicity against AML blasts and leukemic stem cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Off-the-shelf allogeneic T cells engineered with a chimeric antigen receptor targeting CLL-1 (CLEC12A) recognize AML blasts and leukemic stem cells; antigen binding activates the CAR signaling domain to drive T-cell activation and cytotoxic killing of target cells via perforin/granzyme release and cytokines.
drug_name
CLL-1-specific universal CAR T cells
nct_id_drug_ref
NCT05995041